Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq: GTH), a leading precision oncology company in China that
specializes in offering molecular profiling tests, today announced
its unaudited financial results for the second quarter ended
June 30, 2020.
Second Quarter 2020 Unaudited Financial
and Operating Highlights
- Recorded total revenue of RMB101.7
million for the second quarter 2020, representing a 40.3% increase
over the same period of 2019.
- Reported diagnosis and monitoring
revenue of RMB 93.9 million for the second quarter 2020,
representing a 52.1% increase from the same period of 2019.
- Reported gross margin improved to
63.1% for the second quarter 2020, compared to 47.8% in the same
period of 2019.
- Presented data at the American
Association for Cancer Research (AACR) Virtual Annual Meeting
II that highlighted Genetron Health’s industry-leading
technological capability.
- Deepened collaboration with Thermo
Fisher Scientific for joint marketing in China.
- Received US FDA approval for
emergency use of Genetron SARS-CoV-2 RNA Test in June 2020.
- Strengthened the leadership team by
appointing the former U.S. FDA senior officer, Yun-Fu Hu, PhD, as
Chief Medical Officer.
- Successfully completed the initial
public offering (“IPO”) in June 2020 and raised approximately
US$235.0 million of net proceeds.
“During the second quarter of 2020, our business
rebounded as economic and social activities gradually resumed in
China upon the easing of restrictions related to COVID-19. However,
towards the later part of the second quarter, Beijing experienced a
second wave of an outbreak, which has caused some negative impact
on our business,” remarked Mr. Sizhen Wang, co-founder and CEO of
Genetron Health. “Despite these challenges, we are pleased with our
second quarter financial results as our robust top-line growth was
accompanied by strong gross margins and an improved expense
structure. This highlighted the resilience of Genetron Health’s
business and our solid execution in scaling our business.”
“Looking ahead to the second half of 2020, while
we are confident about our fundamental business, and the strength
of our balance sheet following our successful IPO, the COVID-19
pandemic continues to present uncertainties and challenges to all
industry players, including us. We will continue to stay nimble in
the face of changing market conditions, and our long term growth
strategies also remain intact. We intend to continue to expand our
product portfolio for diagnosis and monitoring, develop our
high-value early screening pipeline assets, and to work with
additional biopharmaceutical partners. It is our goal to focus on
the creation of long term shareholder value as we expand our
precision oncology platform,” concluded Mr. Wang.
Second Quarter 2020 Unaudited Financial
ResultsTotal revenue for the second quarter 2020 increased
by 40.3% to RMB101.7 million (US$14.4 million) from RMB72.5 million
in the same period of 2019.
Diagnosis and monitoring revenue increased
by 52.1% to RMB93.9 million (US$13.3 million) in the second quarter
2020 from RMB61.7 million in the same period of 2019. The increase
was mainly driven by the growth in the revenues generated from both
the provision of LDT services and the sale of IVD products.
- Revenue generated from the
provision of LDT services increased by 30.7% to RMB75.8 million
(US$10.7 million) during the second quarter 2020 from RMB58.0
million in the same period of 2019. LDT diagnostic tests sold in
the second quarter 2020 totaled approximately 6,700 units,
representing an increase of 15% compared to the number of LDT
diagnostic tests sold in the same period of 2019. The average
selling price also increased, attributable to a shift to higher
value products such as Genetron Health’s Onco PanScan™.
- Revenue generated from sale of IVD
(In-vitro diagnostic) products increased by 381.4% to RMB18.1
million (US$2.6 million) in the second quarter 2020 from RMB3.8
million in the second quarter 2019. The increase was mainly driven
by the increase in the number of assays and sequencing platforms
sold in the second quarter 2020, notably the Genetron S5 instrument
and Lung 8 Assay.
Revenue generated from development services
decreased by 27.3% to RMB7.8 million (US$1.1 million) in the second
quarter 2020, from RMB10.8 million in the same period of 2019. The
change mainly resulted from the decrease in sequencing services,
reflecting the adjustment of the Company’s business strategy
towards biopharmaceutical services as reflected in the increased
revenue from biopharmaceutical services recorded in the second
quarter 2020.
Despite higher revenue, cost of revenue remained
relatively stable at RMB37.5 million (US$5.3 million) for the three
months ended June 30, 2020, compared to RMB37.8 million in the same
period of 2019.
Gross profit increased by 85.3% to RMB64.2
million (US$9.1 million) in the second quarter 2020 from RMB34.7
million in the same period of 2019. Gross margin increased to 63.1%
for the second quarter of 2020, compared to 47.8% in the same
period of 2019. The change was mainly attributable to the improved
scale, operational optimization, and better product mix.
Operating expenses increased by 15.6% to
RMB117.4 million (US$16.6 million) for the three months ended June
30, 2020, from RMB101.5 million in the same period of 2019.
Selling expenses decreased by 7.1% to RMB60.6
million (US$8.6 million) in the second quarter 2020 from RMB65.2
million in the same period of 2019. Selling expenses as a
percentage of revenues decreased to 59.6% in the second quarter
2020 from 90.0% in the same period of 2019. These decreases were
primarily due to improvement in sales productivity, and limited
travel and marketing activities amid the COVID-19 impact.
Administrative expenses increased by 0.2% to
RMB27.9 million (US$4.0 million) in the second quarter 2020 from
RMB27.8 million in the same period of 2019. Administrative expenses
as a percentage of revenues decreased to 27.4% in the second
quarter 2020 from 38.4% in the second quarter 2019, reflecting the
benefit of improved operational scale.
Research and development expenses increased by
55.7% to RMB29.8 million (US$4.2 million) in the second quarter
2020 from RMB19.2 million in the same period of 2019. The increase
was driven by continued innovation efforts inclusive of development
of new products and technologies. Research and development expenses
as a percentage of revenues increased to 29.3% in the second
quarter of 2020 from 26.4% in the same period of 2019.
Other income-net was RMB1.3 million (US$0.2
million) in the second quarter of 2020, decreased from RMB10.5
million in the same period of 2019. The decrease was mainly due to
reduced government subsidies.
As a result of the above, operating loss
decreased by 20.6% to RMB53.1 million (US$7.5 million) for the
three months ended June 30, 2020, from RMB66.9 million for the
three months ended June 30, 2019.
The Company recorded RMB2,778.6 million
(US$393.3 million) and RMB67.8 million in fair value loss of
financial instruments with preferred rights for the three months
ended June 30, 2020 and 2019, respectively. The fair value loss of
financial instruments with preferred rights was primarily
attributable to the change in the fair value of preferred shares.
Preferred shares were attached with certain key preferred rights,
including anti-dilution rights, liquidation preference and
redemption rights. With the significant increase of valuation
immediately prior to the IPO during the second quarter of 2020, the
fair value loss of financial instruments with preferred rights
recorded in the same quarter increased significantly. At the
completion of the IPO, all preferred shares were converted to
ordinary shares. As a result, in compliance with IFRS, the carrying
value of the financial instruments with preferred rights under
non-current liabilities was derecognized and the same amount was
recorded into total shareholders’ equity. In the future, the fair
value loss of financial instruments will no longer reoccur.
Net loss for the period was RMB2,832.4 million
(US$400.9 million) for the three months ended June 30, 2020,
compared to RMB135.7 million for the three months ended June 30,
2019.
Non-IFRS net loss for the period, defined as net
loss for the period excluding share-based compensation expenses,
fair value change and other loss of financial instruments with
preferred rights, was RMB43.9 million (US$6.2 million) for the
three months ended June 30, 2020, compared to RMB58.8 million for
the three months ended June 30, 2019.
Basic net loss per ordinary share was RMB17.04
(US$2.41) for the second quarter of 2020, compared with a basic net
loss per ordinary share of RMB1.09 for the same period of 2019.
Excluding share-based compensation expenses, fair value change of
financial instruments with preferred rights and other loss of
financial instruments with preferred rights, non-IFRS basic net
loss per ordinary share was RMB0.26 (US$0.04) for the second
quarter of 2020, compared with non-IFRS basic net loss per ordinary
share of RMB0.47 for the same period of 2019. Diluted net loss per
ordinary share is equivalent to basic net loss per ordinary share.
Each ADS represents of five ordinary shares, par value US$0.00002
per share.
Cash, cash equivalents and financial assets at
fair value were RMB1,891.3 million (US$267.7 million) as of June
30, 2020. In June 2020, Genetron Health completed its IPO and
raised approximately US$235.0 million of net proceeds after
deducting underwriting discounts and commissions and estimated
offering expenses payable.
Conference CallA conference
call and webcast to discuss the results will be held at 8:30 a.m.
U.S. Eastern Time on August 6, 2020 (or at 8:30 pm Beijing Time on
August 6, 2020). Interested parties may listen to the conference
call by dialing numbers below:
United States: |
+1 845-675-0437 |
China Domestic: |
400-620-8038 |
Hong Kong: |
+852-3018-6771 |
International: |
+65-6713-5090 |
Conference ID: |
1969177 |
Participants are encouraged to dial into the
call at least 15 minutes in advance due to high call volumes.
The replay will be accessible through September
6, 2020, by dialing the following numbers:
United States: |
+1-646-254-3697 |
International: |
+61-2-8199-0299 |
Conference ID: |
1969177 |
A simultaneous webcast of the conference call
will be available on the "News and Events" page of the Investors
section of the Company's website. A replay of the webcast will be
available for 30 days following the event. For more information,
please visit ir.genetronhealth.com.
About Genetron Holdings
LimitedGenetron Holdings Limited (“Genetron Health” or the
“Company”) (Nasdaq: GTH) is a leading precision oncology platform
company in China that specializes in cancer molecular profiling and
harnesses advanced technologies in molecular biology and data
science to transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor StatementThis press
release contains forward-looking statements. These statements are
made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Exchange Rate InformationAll
translations made in the financial statements or elsewhere in this
press release made from RMB into United States dollars (“US$”) are
solely for convenience and calculated at the rate of
US$1.00=RMB7.0651, representing the exchange rate as of June 30,
2020, set forth in the H.10 statistical release of the U.S. Federal
Reserve Board. No representation is made that the RMB amounts could
have been, or could be, converted, realized or settled into US$ at
that rate, or at any other rate, on June 30, 2020.
Non-IFRS Financial MeasuresThe
Company uses non-IFRS net loss and non-IFRS net loss per ordinary
share for the year/period, which are non-IFRS financial measures,
in evaluating its operating results and for financial and
operational decision-making purposes. The Company believes that
non-IFRS net loss and non-IFRS net loss per ordinary share help
identify underlying trends in the Company's business that could
otherwise be distorted by the effect of certain expenses that the
Company includes in its loss for the year/period. The Company
believes that non-IFRS net loss and non-IFRS net loss per ordinary
share for the year/period provide useful information about its
results of operations, enhances the overall understanding of its
past performance and future prospects and allows for greater
visibility with respect to key metrics used by its management in
its financial and operational decision-making.
Non-IFRS net loss and non-IFRS net loss per
ordinary share for the year/period should not be considered in
isolation or construed as an alternative to operating profit, net
loss for the year/period or any other measure of performance or as
an indicator of its operating performance. Investors are encouraged
to review non-IFRS net loss and non-IFRS net loss per ordinary
share for the year/period and the reconciliation to its most
directly comparable IFRS measures. Non-IFRS net loss and non-IFRS
net loss per ordinary share for the year/period presented here may
not be comparable to similarly titled measures presented by other
companies. Other companies may calculate similarly titled measures
differently, limiting their usefulness as comparative measures to
the Company's data. The Company encourages investors and others to
review its financial information in its entirety and not rely on a
single financial measure.
Non-IFRS net loss and non-IFRS net loss per
ordinary share for the year/period represent net loss for the
year/period excluding share-based compensation expenses, fair value
change of financial instruments with preferred rights and other
loss of financial instruments with preferred rights (if
applicable).
Please see the “Unaudited Non-IFRS Financial
Measure” included in this press release for a full reconciliation
of non-IFRS net loss for the year/period to net loss for the
year/period and non-IFRS net loss per ordinary share for the
year/period to net loss per ordinary share for the year/period.
Investor Relations
ContactUS:Hoki LukHead of Investor RelationsEmail:
hoki.luk@genetronhealth.comPhone: +1 (408) 891-9255
Stephanie CarringtonWestwicke, an ICR CompanyEmail:
Stephanie.Carrington@westwicke.comOffice: +1 (646) 277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.comir@genetronhealth.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408pr@genetronhealth.com
GENETRON HOLDINGS LIMITED |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
LOSS |
|
|
|
|
|
For the three months ended |
|
For the six months ended |
|
|
|
June 30, 2019 |
June 30, 2020 |
|
June 30, 2019 |
June 30, 2020 |
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
Revenue |
72,490 |
|
101,735 |
|
14,400 |
|
|
139,141 |
|
178,578 |
|
25,276 |
|
Cost of
revenue |
(37,832 |
) |
(37,512 |
) |
(5,309 |
) |
|
(75,917 |
) |
(72,117 |
) |
(10,207 |
) |
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
Gross profit |
34,658 |
|
64,223 |
|
9,091 |
|
|
63,224 |
|
106,461 |
|
15,069 |
|
|
------------- |
------------- |
------------- |
|
------------- |
------------- |
------------- |
Selling
expenses |
(65,248 |
) |
(60,618 |
) |
(8,580 |
) |
|
(118,833 |
) |
(114,442 |
) |
(16,198 |
) |
Administrative expenses |
(27,848 |
) |
(27,906 |
) |
(3,950 |
) |
|
(55,055 |
) |
(49,529 |
) |
(7,010 |
) |
Research and
development expenses |
(19,168 |
) |
(29,845 |
) |
(4,224 |
) |
|
(38,584 |
) |
(57,474 |
) |
(8,135 |
) |
Net
impairment losses on financial and contract assets |
244 |
|
(267 |
) |
(38 |
) |
|
(405 |
) |
(990 |
) |
(140 |
) |
Other
income/(loss) - net |
10,471 |
|
1,270 |
|
180 |
|
|
11,554 |
|
(4,332 |
) |
(613 |
) |
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
Operating
expenses |
(101,549 |
) |
(117,366 |
) |
(16,612 |
) |
|
(201,323 |
) |
(226,767 |
) |
(32,096 |
) |
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
Operating loss |
(66,891 |
) |
(53,143 |
) |
(7,521 |
) |
|
(138,099 |
) |
(120,306 |
) |
(17,027 |
) |
|
------------- |
------------- |
------------- |
|
------------- |
------------- |
------------- |
Finance
income |
84 |
|
198 |
|
28 |
|
|
412 |
|
228 |
|
32 |
|
Finance
costs |
(1,068 |
) |
(827 |
) |
(117 |
) |
|
(1,469 |
) |
(4,375 |
) |
(619 |
) |
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
Finance
costs - net |
(984 |
) |
(629 |
) |
(89 |
) |
|
(1,057 |
) |
(4,147 |
) |
(587 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value
loss of financial instruments with preferred rights |
(67,813 |
) |
(2,778,591 |
) |
(393,284 |
) |
|
(128,007 |
) |
(2,823,370 |
) |
(399,622 |
) |
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
Loss
before income tax |
(135,688 |
) |
(2,832,363 |
) |
(400,894 |
) |
|
(267,163 |
) |
(2,947,823 |
) |
(417,236 |
) |
|
|
|
|
|
|
|
|
Income tax
expense |
- |
|
- |
|
- |
|
|
- |
|
- |
|
- |
|
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
Loss
for the period |
(135,688 |
) |
(2,832,363 |
) |
(400,894 |
) |
|
(267,163 |
) |
(2,947,823 |
) |
(417,236 |
) |
|
═══════ |
═══════ |
═══════ |
|
═══════ |
═══════ |
═══════ |
|
|
|
|
|
|
|
|
Loss
attributable to: |
|
|
|
|
|
|
|
Owners of
the Company |
(135,688 |
) |
(2,832,363 |
) |
(400,894 |
) |
|
(267,163 |
) |
(2,947,823 |
) |
(417,236 |
) |
|
═══════ |
═══════ |
═══════ |
|
═══════ |
═══════ |
═══════ |
Loss
per share |
RMB |
|
RMB |
|
USD |
|
|
RMB |
|
RMB |
|
USD |
|
-Basic and
diluted |
(1.09 |
) |
(17.04 |
) |
(2.41 |
) |
|
(2.18 |
) |
(20.25 |
) |
(2.87 |
) |
|
═══════ |
═══════ |
═══════ |
|
═══════ |
═══════ |
═══════ |
Loss
per ADS |
|
|
|
|
|
|
|
-Basic and
diluted |
|
(85.22 |
) |
(12.06 |
) |
|
|
(101.23 |
) |
(14.33 |
) |
|
|
═══════ |
═══════ |
|
|
═══════ |
═══════ |
Shares used in loss per ordinary share
computation: |
|
|
|
|
|
|
|
-Basic and
diluted |
124,268,051 |
166,179,400 |
166,179,400 |
|
122,767,748 |
145,604,263 |
145,604,263 |
ADS
used in loss per ADS computation: |
|
|
|
|
|
|
|
-Basic and
diluted |
|
33,235,880 |
33,235,880 |
|
|
29,120,853 |
29,120,853 |
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITED |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNAUDITED NON-IFRS FINANCIAL MEASURES |
|
|
|
|
|
|
|
|
For the three months ended, |
|
For the six months ended, |
|
|
|
|
|
June 30, 2019 |
|
June
30, 2020 |
|
June 30, 2019 |
|
June 30,
2020 |
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
for the period |
(135,688 |
) |
(2,832,363 |
) |
(400,894 |
) |
|
(267,163 |
) |
(2,947,823 |
) |
(417,236 |
) |
|
Adjustments: |
|
|
|
|
|
|
|
|
Share-based
compensation |
9,124 |
|
9,903 |
|
1,402 |
|
|
20,739 |
|
14,954 |
|
2,117 |
|
|
Fair value
loss of financial instruments with preferred rights |
67,813 |
|
2,778,591 |
|
393,284 |
|
|
128,007 |
|
2,823,370 |
|
399,622 |
|
|
|
─────── |
─────── |
─────── |
|
─────── |
─────── |
─────── |
|
Non-IFRS Net Loss |
(58,751 |
) |
(43,869 |
) |
(6,208 |
) |
|
(118,417 |
) |
(109,499 |
) |
(15,497 |
) |
|
|
═══════ |
═══════ |
═══════ |
|
═══════ |
═══════ |
═══════ |
|
Attributable to: |
|
|
|
|
|
|
|
|
Owners of
the Company |
(58,751 |
) |
(43,869 |
) |
(6,208 |
) |
|
(118,417 |
) |
(109,499 |
) |
(15,497 |
) |
|
|
|
|
|
|
|
|
|
|
Non-IFRS loss per share |
RMB |
|
RMB |
|
USD |
|
|
RMB |
|
RMB |
|
USD |
|
|
-Basic and
diluted |
(0.47 |
) |
(0.26 |
) |
(0.04 |
) |
|
(0.96 |
) |
(0.75 |
) |
(0.11 |
) |
|
|
|
|
|
|
|
|
|
|
Non-IFRS loss per ADS(5 ordinary shares equal to 1
ADS) |
|
|
|
|
|
|
|
|
-Basic and
diluted |
|
(1.32 |
) |
(0.19 |
) |
|
|
(3.76 |
) |
(0.53 |
) |
|
|
|
|
|
|
|
|
|
|
Shares used in non-IFRS loss per ordinary share
computation: |
|
|
|
|
|
|
|
|
-Basic and
diluted |
124,268,051 |
166,179,400 |
166,179,400 |
|
122,767,748 |
145,604,263 |
145,604,263 |
|
|
|
|
|
|
|
|
|
|
ADS
used in non-IFRS loss per ADS computation: |
|
|
|
|
|
|
|
|
-Basic and
diluted |
|
33,235,880 |
33,235,880 |
|
|
29,120,853 |
29,120,853 |
|
|
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITED |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNAUDITED REVENUE AND SEGMENT INFORMATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnosis andmonitoring |
|
Diagnosis andmonitoring |
|
Developmentservices |
|
Total |
|
-
provision of LDTservices |
- sale of IVDproducts |
|
|
RMB’000 |
|
RMB’000 |
|
RMB’000 |
|
RMB’000 |
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, 2019 |
|
|
|
|
|
|
|
|
Revenue |
57,967 |
|
3,769 |
|
10,754 |
|
|
72,490 |
|
Segment profit/(loss) |
36,499 |
|
1,344 |
|
(3,185 |
) |
|
34,658 |
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, 2020 |
|
|
|
|
|
|
|
|
Revenue |
75,772 |
|
18,145 |
|
7,818 |
|
|
101,735 |
|
Segment profit |
53,094 |
|
10,040 |
|
1,089 |
|
|
64,223 |
|
|
|
|
|
|
|
|
|
|
Six
months ended June 30, 2019 |
|
|
|
|
|
|
|
|
Revenue |
108,743 |
|
4,944 |
|
25,454 |
|
|
139,141 |
|
Segment profit/(loss) |
66,928 |
|
1,869 |
|
(5,573 |
) |
|
63,224 |
|
|
|
|
|
|
|
|
|
|
Six
months ended June 30, 2020 |
|
|
|
|
|
|
|
|
Revenue |
123,348 |
|
37,358 |
|
17,872 |
|
|
178,578 |
|
Segment profit/(loss) |
81,749 |
|
25,388 |
|
(676 |
) |
|
106,461 |
|
|
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITED |
|
|
|
|
|
|
|
|
|
|
|
UNAUDITED CONDENSED CONSOLIDATED BALANCE
SHEETS |
|
|
|
|
|
|
|
|
|
|
|
As at
December 31, 2019 |
As at June
30, 2020 |
|
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
|
ASSETS |
|
|
|
|
|
Non-current assets |
|
|
|
|
|
Property, plant and equipment |
|
83,013 |
|
75,397 |
|
10,672 |
|
|
Right-of-use
assets |
|
43,182 |
|
37,140 |
|
5,257 |
|
|
Intangible
assets |
|
5,482 |
|
6,604 |
|
935 |
|
|
Prepayments |
|
12,679 |
|
9,841 |
|
1,393 |
|
|
|
|
──────── |
──────── |
──────── |
|
Total non-current assets |
|
144,356 |
|
128,982 |
|
18,257 |
|
|
|
|
──────── |
──────── |
──────── |
|
Current assets |
|
|
|
|
|
Inventories |
|
17,896 |
|
18,192 |
|
2,575 |
|
|
Contract
assets |
|
1,020 |
|
886 |
|
125 |
|
|
Other
current assets |
|
43,711 |
|
39,698 |
|
5,619 |
|
|
Trade
receivables |
|
83,757 |
|
98,640 |
|
13,962 |
|
|
Other
receivables and prepayments |
|
19,526 |
|
14,843 |
|
2,100 |
|
|
Amounts due
from related parties |
|
1,064 |
|
827 |
|
117 |
|
|
Financial
assets at fair value through profit or loss |
|
122,224 |
|
47,722 |
|
6,755 |
|
|
Cash and
cash equivalents |
|
139,954 |
|
1,843,531 |
|
260,935 |
|
|
|
|
──────── |
──────── |
──────── |
|
Total current assets |
|
429,152 |
|
2,064,339 |
|
292,188 |
|
|
|
|
──────── |
──────── |
──────── |
|
Total assets |
|
573,508 |
|
2,193,321 |
|
310,445 |
|
|
|
|
════════ |
════════ |
════════ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As at
December 31, 2019 |
As at June 30, 2020 |
|
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
Financial
instruments with preferred rights |
|
2,106,334 |
|
- |
|
- |
|
|
Borrowings |
|
3,643 |
|
1,820 |
|
258 |
|
|
Lease
liabilities |
|
29,124 |
|
23,538 |
|
3,332 |
|
|
|
|
──────── |
──────── |
──────── |
|
Total non-current liabilities |
|
2,139,101 |
|
25,358 |
|
3,590 |
|
|
|
|
──────── |
──────── |
──────── |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade
payables |
|
49,955 |
|
37,940 |
|
5,369 |
|
|
Contract
liabilities |
|
18,189 |
|
5,619 |
|
795 |
|
|
Other
payables and accruals |
|
109,683 |
|
101,282 |
|
14,337 |
|
|
Amounts due
to related parties |
|
34 |
|
34 |
|
5 |
|
|
Borrowings |
|
19,514 |
|
49,176 |
|
6,960 |
|
|
Lease
liabilities |
|
15,363 |
|
18,188 |
|
2,574 |
|
|
|
|
──────── |
──────── |
──────── |
|
Total current liabilities |
|
212,738 |
|
212,239 |
|
30,040 |
|
|
|
|
──────── |
──────── |
──────── |
|
Total liabilities |
|
2,351,839 |
|
237,597 |
|
33,630 |
|
|
|
|
──────── |
──────── |
──────── |
|
Net
(liabilities)/assets |
|
(1,778,331 |
) |
1,955,724 |
|
276,815 |
|
|
|
|
════════ |
════════ |
════════ |
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS’ (DEFICIT)/EQUITY |
|
|
|
|
|
(Deficit)/equity attributable to owners of the
Company |
|
|
|
Share
capital |
|
17 |
|
59 |
|
8 |
|
|
Share
premium |
|
- |
|
6,657,562 |
|
942,317 |
|
|
Treasury
shares |
|
(3,578 |
) |
(2,374 |
) |
(336 |
) |
|
Other
reserves |
|
69,207 |
|
92,277 |
|
13,061 |
|
|
Accumulated
losses |
|
(1,843,977 |
) |
(4,791,800 |
) |
(678,235 |
) |
|
|
|
──────── |
──────── |
──────── |
|
Total shareholders’ (deficit)/equity |
(1,778,331 |
) |
1,955,724 |
|
276,815 |
|
|
|
|
════════ |
════════ |
════════ |
|
|
|
|
|
|
|
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024